China Biologic Products, Inc.

China Biologic Products, Inc. (NASDAQ: CBPO) is the largest non state owned plasma based biopharmaceutical company approved by the Chinese government. Through our indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guizhou Taibang Biologic Technologies, and our equity investment in Xi€™an Huitian Blood Products, we are a fully integrated provider of plasma-based biopharmaceuticals, with capabilities spanning from plasma collection to and research and development, to product manufacturing and commercialization. Our key products including human albumin, Human Hepatitis B immunoglobin, Human Immunoglobulin for Intravenous Injection, Human Tetanus Immunoglobulin, Human Rabies Immunoglobulin, Human Immunoglobulin, Human Coagulation Factor VIII, Placenta polypeptide are often used to treat life-threatening conditions, such as low albumin, hemophilia and other blood diseases. We currently have *0 marketed plasma-based products and a pipeline of new products to drive future growth in the large Chinese plasma market.